H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015

Description: H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015

Summary

The report ‘H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015’, provides an overview of the H5N1 Infection (Avian Influenza)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for H5N1 Infection (Avian Influenza)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding H5N1 Infection (Avian Influenza) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

- List of Tables
- List of Figures
- Introduction
- Report Coverage
- H5N1 Infection (Avian Influenza) Overview
- Therapeutics Development
- Pipeline Products for H5N1 Infection (Avian Influenza) - Overview
- Pipeline Products for H5N1 Infection (Avian Influenza) - Comparative Analysis
- H5N1 Infection (Avian Influenza) - Therapeutics under Development by Companies
- H5N1 Infection (Avian Influenza) - Therapeutics under Investigation by Universities/Institutes
- H5N1 Infection (Avian Influenza) - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- H5N1 Infection (Avian Influenza) - Products under Development by Companies
- H5N1 Infection (Avian Influenza) - Products under Investigation by Universities/Institutes
- H5N1 Infection (Avian Influenza) - Companies Involved in Therapeutics Development
- Akshaya Bio Inc.
- Altimmune, Inc.
- Antigen Express, Inc.
- Aphiios Corporation
- Aprogen, Inc.
- BioDiem Ltd
- BiondVax Pharmaceuticals Ltd.
- CEL-SCI Corporation
- Cocystal Pharma, Inc.
- CSL Limited
- Daiichi Sankyo Company, Limited
Emergent BioSolutions Inc.
Gemmus Pharma Inc.
GlaxoSmithKline Plc
Green Cross Corporation
Hemispherx Biopharma, Inc.
iBio, Inc.
Immunovaccine, Inc.
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Kineta, Inc.
Medicago Inc.
MedImmune, LLC
Microbiotix, Inc.
Microgen Scientific Industrial Company for Immunobiological Medicines
Myelo Therapeutics GmbH
NanoBio Corporation
Nanotherapeutics, Inc.
NanoViricides, Inc.
NewLink Genetics Corporation
OPKO Health, Inc.
PaxVax, Inc.
PDS Biotechnology Corporation
PeptiDream Inc.
Protein Sciences Corporation
Shionogi & Co., Ltd.
Sirnaomics, Inc.
Takeda Pharmaceutical Company Limited
TechnoVax, Inc.
Theraclone Sciences, Inc.
Vaxine Pty Ltd
Vaxinnate Corporation
H5N1 Infection (Avian Influenza) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

A-06 - Drug Profile

AE-443p - Drug Profile

Alferon LDO - Drug Profile

AP-302 - Drug Profile

APP-0205 - Drug Profile

APP-309 - Drug Profile

AT-301 - Drug Profile

CEL-1000 - Drug Profile

DP-C005 - Drug Profile

FBF-001 - Drug Profile

FDX-000 - Drug Profile

Gamma-Flu - Drug Profile

GP-1001 - Drug Profile

GP-1002 - Drug Profile

GP-1681 - Drug Profile

GREFLU/VIE - Drug Profile

HAI-05 - Drug Profile

iHA-24 - Drug Profile

Influn-1RNA - Drug Profile

influenza (strain H5N1, H1N1) vaccine - Drug Profile

influenza [strain A/H5N1] vaccine - Drug Profile

influenza [strain A/H5N1] vaccine - Drug Profile

influenza [strain H5N1, H7N2, H9N2] virus like particle vaccine - Drug Profile

influenza [strain H5N1] (split virion) vaccine - Drug Profile
influenza [strain H5N1] vaccine - Drug Profile
influenza [strain H5N1] vaccine - Drug Profile
influenza [strain H5N1] vaccine - Drug Profile
influenza [strain H5N1] vaccine - Drug Profile
influenza [strain H5N1] vaccine - Drug Profile
influenza [strain H5N1] vaccine - Drug Profile
influenza [strain H5N1] vaccine - Drug Profile
influenza [strain H5N1] vaccine - Drug Profile
influenza [strain H5N1] vaccine - Drug Profile
influenza [strain H5N1] vaccine - Drug Profile
influenza [strain H5N1] virus like particle vaccine + Glucopyranosyl Lipid A Adjuvant - Drug Profile
influenza [strain H5N1] virus like particles vaccine - Drug Profile
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
influenza A vaccine - Drug Profile
influenza vaccine - Drug Profile
influenza vaccine - Drug Profile
influenza virus like particle vaccine - Drug Profile
Innate Immune Adjuvants - Drug Profile
INO-3510 - Drug Profile
IPS-07 series - Drug Profile
JNJ-872 - Drug Profile
KD-295 - Drug Profile
KIB-PCI - Drug Profile
M-001 - Drug Profile
MBX-2329 - Drug Profile
MBX-2546 - Drug Profile
MEDI-550 - Drug Profile
MG-1109 - Drug Profile
Monoclonal Antibodies to Inhibit H5 HA and H7 HA for Avian Infection - Drug Profile
Monoclonal Antibody to Inhibit Hemagglutinin for Influenza - Drug Profile
MVAH-5HA - Drug Profile
Myelo-001 - Drug Profile
NVINF-1 - Drug Profile
NVINF-2 - Drug Profile
OrniFlu - Drug Profile
PanBlok - Drug Profile
PDS-0102 - Drug Profile
PNSIA-28 - Drug Profile
PNSIA-49 - Drug Profile
PXVX-0103 - Drug Profile
rintatolimod - Drug Profile
S-033188 - Drug Profile
Small Molecules to Activate Sirtuin for Influenza - Drug Profile
Small Molecules to Inhibit Endonuclease for Flu - Drug Profile
STP-702 - Drug Profile
Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile
TCN-032 - Drug Profile
TVX-003 - Drug Profile
VAX-161 - Drug Profile
VGX-3400X - Drug Profile
VH-244 - Drug Profile
H5N1 Infection (Avian Influenza) - Recent Pipeline Updates
H5N1 Infection (Avian Influenza) - Dormant Projects
H5N1 Infection (Avian Influenza) - Discontinued Products
H5N1 Infection (Avian Influenza) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables

Number of Products under Development for H5N1 Infection (Avian Influenza), H2 2015

Number of Products under Development for H5N1 Infection (Avian Influenza) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Development by Companies, H2 2015 (Contd..1)

Number of Products under Development by Companies, H2 2015 (Contd..2)

Number of Products under Development by Companies, H2 2015 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Development by Companies, H2 2015 (Contd..2)

Products under Development by Companies, H2 2015 (Contd..3)

Products under Development by Companies, H2 2015 (Contd..4)

Products under Investigation by Universities/Institutes, H2 2015

H5N1 Infection (Avian Influenza) - Pipeline by Akshaya Bio Inc., H2 2015

H5N1 Infection (Avian Influenza) - Pipeline by AlImmune, Inc., H2 2015

H5N1 Infection (Avian Influenza) - Pipeline by Antigen Express, Inc., H2 2015

H5N1 Infection (Avian Influenza) - Pipeline by Aphios Corporation, H2 2015

H5N1 Infection (Avian Influenza) - Pipeline by Aprogen, Inc., H2 2015

H5N1 Infection (Avian Influenza) - Pipeline by BioDiem Ltd, H2 2015

H5N1 Infection (Avian Influenza) - Pipeline by BlondVax Pharmaceuticals Ltd., H2 2015

H5N1 Infection (Avian Influenza) - Pipeline by CEL-SCI Corporation, H2 2015

H5N1 Infection (Avian Influenza) - Pipeline by Cocrystal Pharma, Inc., H2 2015

H5N1 Infection (Avian Influenza) - Pipeline by CSL Limited, H2 2015

H5N1 Infection (Avian Influenza) - Pipeline by Daiichi Sankyo Company, Limited, H2 2015

H5N1 Infection (Avian Influenza) - Pipeline by Emergent BioSolutions Inc., H2 2015

H5N1 Infection (Avian Influenza) - Pipeline by Gemmus Pharma Inc., H2 2015

H5N1 Infection (Avian Influenza) - Pipeline by GlaxoSmithKline Plc, H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Green Cross Corporation, H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Hemispherx Biopharma, Inc., H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by iBio, Inc., H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Immunovaccine, Inc., H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Johnson & Johnson, H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Kineta, Inc., H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Medicago Inc., H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by MedImmune, LLC, H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Microbiotix, Inc., H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Microgen Scientific Industrial Company for Immunobiological Medicines, H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Myelo Therapeutics GmbH, H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by NanoBio Corporation, H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Nanotherapeutics, Inc., H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by NanoViricides, Inc., H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by NewLink Genetics Corporation, H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by OPKO Health, Inc., H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by PaxVax, Inc., H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by PDS Biotechnology Corporation, H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by PeptiDream Inc., H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Protein Sciences Corporation, H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Shionogi & Co., Ltd., H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Sirnaomics, Inc., H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by TechnoVax, Inc., H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Theraclone Sciences, Inc., H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by Vaxine Pty Ltd, H2 2015
H5N1 Infection (Avian Influenza) - Pipeline by VaxInnate Corporation, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
H5N1 Infection (Avian Influenza) Therapeutics - Recent Pipeline Updates, H2 2015
H5N1 Infection (Avian Influenza) - Dormant Projects, H2 2015
H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..1), H2 2015
H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..2), H2 2015
H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..3), H2 2015
H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..4), H2 2015
H5N1 Infection (Avian Influenza) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for H5N1 Infection (Avian Influenza), H2 2015
Number of Products under Development for H5N1 Infection (Avian Influenza) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3600500/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015
Web Address: http://www.researchandmarkets.com/reports/3600500/
Office Code: SCDKTLWK

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>✔️</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>✔️</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>✔️</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: __________________________________________ Last Name: __________________________________________
Email Address: * __________________________________________
Job Title: __________________________________________
Organisation: __________________________________________
Address: __________________________________________
City: __________________________________________
Postal / Zip Code: __________________________________________
Country: __________________________________________
Phone Number: __________________________________________
Fax Number: __________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:
You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:
Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World